{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T03:17:46Z","timestamp":1761621466878,"version":"3.37.3"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T00:00:00Z","timestamp":1565222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T00:00:00Z","timestamp":1565222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Actinic keratosis (AK) is a skin premalignant lesion, which progresses into squamous cell carcinoma (SCC) if left untreated. Ingenol mebutate gel is approved for local treatment of non-hyperkeratotic, non-hypertrophic AK; it also has the potential to act as a field cancerization therapy to prevent the progression of AK to SCC. To gain better insights into the mechanisms of ingenol mebutate beyond the mere clinical assessment, we investigated, for the first time, the metabolome of skin tissues from patients with AK, before and after ingenol mebutate treatment, with high-resolution magic angle spinning nuclear magnetic resonance spectroscopy. The metabolomic profiles were compared with those of tissues from healthy volunteers. Overall, we identified a number of metabolites, the homeostasis of which became altered during the process of tumorigenesis from healthy skin to AK, and was restored, at least partially, by ingenol mebutate therapy. These metabolites may help to attain a better understanding of keratinocyte metabolism and to unmask the metabolic pathways related to cell proliferation. These results provide helpful information to identify biomarkers with prognostic and therapeutic significance in AK, and suggest that field cancerization therapy with ingenol mebutate may contribute to restore skin metabolism to a normal state in patients with AK.<\/jats:p>","DOI":"10.1038\/s41598-019-47984-x","type":"journal-article","created":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T10:20:54Z","timestamp":1565259654000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Field cancerization therapy with ingenol mebutate contributes to restoring skin-metabolism to normal-state in patients with actinic keratosis: a metabolomic analysis"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2394-8462","authenticated-orcid":false,"given":"Valeria","family":"Righi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6243-6166","authenticated-orcid":false,"given":"Elisabetta","family":"Tarentini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3303-8761","authenticated-orcid":false,"given":"Adele","family":"Mucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla","family":"Reggiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Cecilia","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Casari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Magnoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,8]]},"reference":[{"key":"47984_CR1","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1080\/09546634.2016.1254328","volume":"28","author":"T Dirschka","year":"2017","unstructured":"Dirschka, T. et al. Real-world approach to actinic keratosis management: practical treatment algorithm for office-based dermatology. J Dermatolog Treat 28, 431\u2013442 (2017).","journal-title":"J Dermatolog Treat"},{"key":"47984_CR2","first-page":"379","volume":"150","author":"A Filosa","year":"2015","unstructured":"Filosa, A. & Filosa, G. Actinic keratosis and squamous cell carcinoma: clinical and pathological features. G Ital Dermatol Venereol 150, 379\u2013384 (2015).","journal-title":"G Ital Dermatol Venereol"},{"key":"47984_CR3","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/bjd.14852","volume":"177","author":"JA Siegel","year":"2017","unstructured":"Siegel, J. A., Korgavkar, K. & Weinstock, M. A. Current perspective on actinic keratosis: a review. Br J Dermatol 177, 350\u2013358 (2017).","journal-title":"Br J Dermatol"},{"key":"47984_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/jdv.14151","volume":"31","author":"MT Fernandez Figueras","year":"2017","unstructured":"Fernandez Figueras, M. T. From actinic keratosis to squamous cell carcinoma: pathophysiology revisited. J Eur Acad Dermatol Venereol 31, 5\u20137 (2017).","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"47984_CR5","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.plipres.2012.10.003","volume":"52","author":"AC Kendall","year":"2013","unstructured":"Kendall, A. C. & Nicolaou, A. Bioactive lipid mediators in skin inflammation and immunity. Prog Lipid Res 52, 141\u2013164 (2013).","journal-title":"Prog Lipid Res"},{"key":"47984_CR6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1159\/000366531","volume":"46","author":"J Wei","year":"2015","unstructured":"Wei, J., Kok, L. F., Byrne, S. N. & Halliday, G. M. Photodamage: all signs lead to actinic keratosis and early squamous cell carcinoma. Curr Probl Dermatol 46, 14\u201319 (2015).","journal-title":"Curr Probl Dermatol"},{"key":"47984_CR7","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1172\/JCI57415","volume":"122","author":"V Ratushny","year":"2012","unstructured":"Ratushny, V., Gobe, M. D., Hick, R., Ridky, T. W. & Seykora, J. T. From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamos cell carcinoma. J Clin Invest. 122, 464\u2013462 (2012).","journal-title":"J Clin Invest."},{"key":"47984_CR8","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.2174\/1871520617666170213130523","volume":"17","author":"K Kostovic","year":"2017","unstructured":"Kostovic, K., Gulin, S. J., Mokos, Z. B. & Ceovic, R. Topical ingenol mebutate: a new treatment modality for multiple actinic keratoses and field cancerization. Anticancer Agents Med Chem 17, 1304\u20131311 (2017).","journal-title":"Anticancer Agents Med Chem"},{"key":"47984_CR9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/bjd.14968","volume":"176","author":"M Ulrich","year":"2017","unstructured":"Ulrich, M., Reinhold, U., Skov, T., Elvang Sondergaard, R. & Guitera, P. Histological examination confirms clinical clearance of actinic keratoses following treatment with ingenol mebutate 0.05% gel. Br J Dermatol 176, 71\u201380 (2017).","journal-title":"Br J Dermatol"},{"key":"47984_CR10","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1111\/jdv.13211","volume":"29","author":"G Pellacani","year":"2015","unstructured":"Pellacani, G. et al. A randomized trial comparing simultaneous vs. sequential field treatment of actinic keratosis with ingenol mebutate on two separate areas of the head and body. J Eur Acad Dermatol Venereol 29, 2192\u20132198 (2015).","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"47984_CR11","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1056\/NEJMoa1111170","volume":"366","author":"M Lebwohl","year":"2012","unstructured":"Lebwohl, M. et al. Ingenol mebutate gel for actinic keratosis. N Engl J Med 366, 1010\u20131019 (2012).","journal-title":"N Engl J Med"},{"key":"47984_CR12","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1001\/jamadermatol.2013.2766","volume":"149","author":"M Lebwohl.","year":"2013","unstructured":"Lebwohl., M. et al. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol 149, 666\u2013670 (2013).","journal-title":"JAMA Dermatol"},{"key":"47984_CR13","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/bjd.14222","volume":"174","author":"C Garbe","year":"2016","unstructured":"Garbe, C. et al. Efficacy and safety of follow-up field treatment of actinic keratosis with ingenol mebutate 0.015% gel: a randomized, controlled 12-month study. Br J Dermatol 174, 505\u2013513 (2016).","journal-title":"Br J Dermatol"},{"key":"47984_CR14","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/jdv.13831","volume":"31","author":"I Bobyr","year":"2017","unstructured":"Bobyr, I. et al. Ingenol mebutate in actinic keratosis: a clinical, videodermoscopic and immunohistochemical study. J Eur Acad Dermatol Venereol 31, 260\u2013266 (2017).","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"47984_CR15","first-page":"741","volume":"13","author":"B Berman","year":"2014","unstructured":"Berman, B. et al. Efficacy and safety of ingenol mebutate 0.015% gel after cryosurgery of actinic keratosis: 12-month results. J Drugs Dermatol 13, 741\u2013747 (2014).","journal-title":"J Drugs Dermatol"},{"key":"47984_CR16","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s13555-014-0061-2","volume":"4","author":"DR Alchin","year":"2014","unstructured":"Alchin, D. R. Ingenol mebutate: a succinct review of a succinct therapy. Dermatol Ther (Heidelb) 4, 157\u2013164 (2014).","journal-title":"Dermatol Ther (Heidelb)"},{"key":"47984_CR17","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1111\/jdv.14803","volume":"32","author":"R Pampena","year":"2018","unstructured":"Pampena, R. et al. Tracking actinic keratosis of face and scalp treated with 0.015% ingenol mebutate to identify clinical and dermoscopic predictors of treatment response. J Eur Acad Dermatol Venereol 32, 1461\u20131468 (2018).","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"47984_CR18","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.gpb.2015.04.002","volume":"13","author":"S Jiang","year":"2015","unstructured":"Jiang, S., Hinchliffe, T. E. & Wu, T. Biomarkers of An Autoimmune Skin Disease-Psoriasis. Genomics Proteomics Bioinformatics 13, 224\u2013233 (2015).","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"47984_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s11306-016-1093-7","volume":"12","author":"EG Armitage","year":"2016","unstructured":"Armitage, E. G. & Southam, A. D. Monitoring cancer prognosis, diagnosis and treatment efficacy using metabolomics and lipidomics. Metabolomics 12, 146 (2016).","journal-title":"Metabolomics"},{"key":"47984_CR20","doi-asserted-by":"publisher","first-page":"715","DOI":"10.2147\/CMAR.S156837","volume":"10","author":"W Guo","year":"2018","unstructured":"Guo, W., Tan, H. Y., Wang, N., Wang, X. & Feng, Y. Deciphering hepatocellular carcinoma through metabolomics: from biomarker discovery to therapy evaluation. Cancer Manag Res 10, 715\u2013734 (2018).","journal-title":"Cancer Manag Res"},{"key":"47984_CR21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1046\/j.1467-2494.2003.00174.x","volume":"25","author":"AV Rawlings","year":"2003","unstructured":"Rawlings, A. V. Trends in stratum corneum research and the management of dry skin conditions. Int J Cosmet Sci 25, 63\u201395 (2003).","journal-title":"Int J Cosmet Sci"},{"key":"47984_CR22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.drup.2016.06.004","volume":"28","author":"S Raz","year":"2016","unstructured":"Raz, S., Stark, M. & Assaraf, Y. G. Folylpoly-gamma-glutamate synthetase: A key determinant of folate homeostasis and antifolate resistance in cancer. Drug Resist Updat 28, 43\u201364 (2016).","journal-title":"Drug Resist Updat"},{"key":"47984_CR23","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1126\/science.1218595","volume":"336","author":"M Jain","year":"2012","unstructured":"Jain, M. et al. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science (New York, N.Y.) 336, 1040\u20131044 (2012).","journal-title":"Science (New York, N.Y.)"},{"key":"47984_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/srep45057","volume":"7","author":"JM Moilanen","year":"2017","unstructured":"Moilanen, J. M. et al. Significant role of collagen XVII and integrin beta4 in migration and invasion of the less aggressive squamous cell carcinoma cells. Sci Rep 7, 45057 (2017).","journal-title":"Sci Rep"},{"key":"47984_CR25","doi-asserted-by":"publisher","first-page":"e90367","DOI":"10.1371\/journal.pone.0090367","volume":"9","author":"M Randhawa","year":"2014","unstructured":"Randhawa, M., Sangar, V., Tucker-Samaras, S. & Southall, M. Metabolic signature of sun exposed skin suggests catabolic pathway overweighs anabolic pathway. PLoS One 9, e90367, https:\/\/doi.org\/10.1371\/journal.pone.0090367 (2014).","journal-title":"PLoS One"},{"key":"47984_CR26","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/apha.12365","volume":"213","author":"IH Lambert","year":"2015","unstructured":"Lambert, I. H., Kristensen, D. M., Holm, J. B. & Mortensen, O. H. Physiological role of taurine\u2013from organism to organelle. Acta Physiol 213, 191\u2013212 (2015).","journal-title":"Acta Physiol"},{"key":"47984_CR27","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/j.0022-202X.2004.23313.x","volume":"123","author":"U Warskulat","year":"2004","unstructured":"Warskulat, U., Reinen, A., Grether-Beck, S., Krutmann, J. & Haussinger, D. The osmolyte strategy of normal human keratinocytes in maintaining cell homeostasis. J Invest Dermatol 123, 516\u2013521 (2004).","journal-title":"J Invest Dermatol"},{"key":"47984_CR28","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.4049\/jimmunol.179.6.3604","volume":"179","author":"N Rockel","year":"2007","unstructured":"Rockel, N. et al. The osmolyte taurine protects against ultraviolet B radiation-induced immunosuppression. J Immunol 179, 3604\u20133612 (2007).","journal-title":"J Immunol"},{"key":"47984_CR29","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.molcel.2015.10.018","volume":"60","author":"GM DeNicola","year":"2015","unstructured":"DeNicola, G. M. & Cantley, L. C. Cancer\u2019s fuel choice: new flavors for a picky eater. Mol Cell 60, 514\u2013523 (2015).","journal-title":"Mol Cell"},{"key":"47984_CR30","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","volume":"41","author":"MV Liberti","year":"2016","unstructured":"Liberti, M. V. & Locasale, J. W. The Warburg Effect: How Does it Benefit Cancer Cells? Trends Biochem Sci 41, 211\u2013218 (2016).","journal-title":"Trends Biochem Sci"},{"key":"47984_CR31","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.semnephrol.2018.01.006","volume":"38","author":"RH Weiss","year":"2018","unstructured":"Weiss, R. H. Metabolomics and metabolic reprogramming in kidney cancer. Semin Nephrol 38, 175\u2013182 (2018).","journal-title":"Semin Nephrol"},{"key":"47984_CR32","doi-asserted-by":"crossref","unstructured":"Kaushik, A. K. & DeBerardinis, R. J. Applications of metabolomics to study cancer metabolism. Biochim Biophys Acta Rev Cancer 1870, 2\u201314 pii:S0304-419X(18)30050-7 (2018).","DOI":"10.1016\/j.bbcan.2018.04.009"},{"key":"47984_CR33","doi-asserted-by":"crossref","unstructured":"Pullar, J. M., Carr, A. C. & Vissers, M. C. M. The roles of vitamin C in skin health. Nutrients 9 (2017).","DOI":"10.3390\/nu9080866"},{"key":"47984_CR34","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1002\/anie.201502227","volume":"55","author":"MP Thomas","year":"2016","unstructured":"Thomas, M. P., Mills, S. J. & Potter, B. V. The \u201cother\u201d inositols and their phosphates: synthesis, biology, and medicine (with recent advances in myo-inositol chemistry). Angew Chem Int Ed Engl 55, 1614\u20131650 (2016).","journal-title":"Angew Chem Int Ed Engl"},{"key":"47984_CR35","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1207\/s15327914nc5502_1","volume":"55","author":"I Vucenik","year":"2006","unstructured":"Vucenik, I. & Shamsuddin, A. M. Protection against cancer by dietary IP6 and inositol. Nutr Cancer 55, 109\u2013125 (2006).","journal-title":"Nutr Cancer"},{"key":"47984_CR36","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1194\/jlr.R700019-JLR200","volume":"49","author":"Z Li","year":"2008","unstructured":"Li, Z. & Vance, D. E. Phosphatidylcholine and choline homeostasis. Journal of lipid research 49, 1187\u20131194 (2008).","journal-title":"Journal of lipid research"},{"key":"47984_CR37","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S1096-4959(01)00400-6","volume":"130","author":"E Karna","year":"2001","unstructured":"Karna, E., Miltyk, W., Wolczynski, S. & Palka, J. A. The potential mechanism for glutamine-induced collagen biosynthesis in cultured human skin fibroblasts. Comp Biochem Physiol B Biochem Mol Biol 130, 23\u201332 (2001).","journal-title":"Comp Biochem Physiol B Biochem Mol Biol"},{"key":"47984_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-018-0343-8","volume":"23","author":"SA Braun","year":"2018","unstructured":"Braun, S. A. et al. Ingenol mebutate induces a tumor cell-directed inflammatory response and antimicrobial peptides thereby promoting rapid tumor destruction and wound healing. Eur J Med Res 23, 45 (2018).","journal-title":"Eur J Med Res"},{"key":"47984_CR39","doi-asserted-by":"publisher","first-page":"e0160096","DOI":"10.1371\/journal.pone.0160096","volume":"11","author":"S Emmert","year":"2016","unstructured":"Emmert, S. et al. Tumor-Preferential Induction of Immune Responses and Epidermal Cell Death in Actinic Keratoses by Ingenol Mebutate. PLoS One 11, e0160096 (2016).","journal-title":"PLoS One"},{"key":"47984_CR40","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1684\/ejd.2015.2570","volume":"25","author":"C Morton","year":"2015","unstructured":"Morton, C. et al. European Dermatology Forum Guidelines on topical photodynamic therapy. Eur J Dermatol. 25, 296\u2013311 (2015).","journal-title":"Eur J Dermatol."},{"key":"47984_CR41","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/cmr.a.20068","volume":"28A","author":"L Schenetti","year":"2006","unstructured":"Schenetti, L. et al. HR\u2010MAS NMR spectroscopy in the characterization of human tissues: Application to healthy gastric mucosa. Concepts in Magnetic Resonance Part A 28A, 430\u2013443 (2006).","journal-title":"Concepts in Magnetic Resonance Part A"},{"key":"47984_CR42","doi-asserted-by":"publisher","first-page":"W486","DOI":"10.1093\/nar\/gky310","volume":"46","author":"J Chong","year":"2018","unstructured":"Chong, J. et al. MetaboAnalyst 4.0: towards more transparent and integrative metabolomics analysis. Nucleic Acids Res 46, W486\u2013W494 (2018).","journal-title":"Nucleic Acids Res"},{"key":"47984_CR43","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1002\/mrm.20909","volume":"55","author":"MG Swanson","year":"2006","unstructured":"Swanson, M. G. et al. Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy. Magn Reson Med 55, 1257\u20131264 (2006).","journal-title":"Magn Reson Med"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-47984-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-47984-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-47984-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T12:19:50Z","timestamp":1671279590000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-47984-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,8]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["47984"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-47984-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2019,8,8]]},"assertion":[{"value":"31 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"11515"}}